



	INVESTMENT HIGHLIGHTS
Commercial Brand	VesCell™
Technology	Autologous regenerative cell therapy (patient's own stem cells)
Commercial Launch	Doctors Hospital, Nassau, The Bahamas
Commercialization	Planned Q4 2026
Lead Markets	Cardiology • PAD • CLTI • Vascular Dementia • Longevity
Business Model	Vertically integrated regenerative medicine

WHY NOW?

- ✓ Commercial launch in The Bahamas - Q4 Revenue
- ✓ One of the largest published autologous regenerative medicine datasets
- ✓ 11 peer-reviewed publications
- ✓ Patented proprietary manufacturing platform
- ✓ Multiple high-value ischemic disease markets addressed
- ✓ Commercial treatments generate revenue **and** real-time clinical trial evidence

VESCELL™ TREATMENTS



Angina



Heart Failure



PAD / CLTI



Vascular Dementia



Longevity

THE VALUE FLYWHEEL

Every treatment simultaneously creates three strategic assets: commercial revenue, clinical trial evidence that supports regulatory applications, and increased physician adoption.

INVESTMENT DASHBOARD

 ECONOMICS	 CLINICAL EVIDENCE	 PATIENT OUTCOMES
Treatments / Day: 4	Patients Treated: 498+	6-Minute Walk Test +80–126 metres
Operating Days: 240	Clinical Trial Subjects: 318	NYHA Functional Class III/IV → II/III
Treatments / Year: 960	Published Clinical Studies: 7	Myocardial Perfusion Defect 38.5% → 21.1%
Average VesCell™ Price: US\$50,000	Peer-Reviewed Publications: 11	LVEF (<20% Baseline) 14.6% → 28.4%
Illustrative Annual VesCell™ Revenue ≈ US\$48 Million	Published Safety Profile Published safety summaries report no cell-related serious adverse events.	Limb Ischemia Significant wound healing and pain reduction

COMMERCIAL PLATFORM



LONGEVITY PROGRAM

Objective	Description
Goal	Increased health-span and quality of life as measured by improvements
Improvements	• Cardiovascular • Executive Function • Immune System
Evidence	Multi-domain clinical outcomes generated and published from treatments to-date
Vision	Evidence supports participation in the XPRIZE Healthspan competition

INVESTMENT THESIS

Hemostemix’ business model leverages its published clinical evidence to substantiate commercialization in seven verticals simultaneously. Rather than treating for revenue only, each patient is enrolled in a commercial clinical trial that generates revenue and real-time data that can be used to open additional markets following regulatory approvals.